Company intelligence / Profile preview

Orica

South San Francisco, California, United States

Ownership: Private
Employees: ~85
Development stage: Other

Overview

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by overcoming resistance in cancer. The company's name is an acronym for its mission: Overcoming Resistance In Cancer. ORIC leverages its proprietary resistance platform to develop small molecule therapies that target diverse mechanisms of resistance, including bypass signaling, lineage plasticity, and target mutations. Its lead programs include ORIC-114, a brain-penetrant inhibitor of EGFR and HER2, and ORIC-944, a potent and selective inhibitor of the PRC2 complex. Headquartered in South San Francisco, the company is led by a team of experienced oncology drug hunters and is publicly traded on the Nasdaq.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Pfizer

Beyond the preview

Go deeper on Orica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orica.

Explore the full profile